Practice
Featured experience
Comcast spinoff of select cable television networks
We are advising Comcast on the transaction
Durational Capital Management strategic investment in Garage Beer
We are advising Durational Capital Management on the transaction
Arcos Dorados renewal of long-term master franchise agreement with McDonald’s
We advised Arcos Dorados on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Davis Polk Advises Roper Technologies on Its Acquisition of RF IDeas
Davis Polk advised Roper Technologies, Inc. in connection with its acquisition of RF IDeas, Inc. The financial terms of the…
Davis Polk Advises SS&C on Its Acquisition of Citigroup’s Alternative Investor Services Business
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its acquisition of Citigroup’s Alternative…
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…
Natera, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000…
Davis Polk Advises Hotel Urbano on its Strategic Partnership with Priceline
Davis Polk advised Hotel Urbano in connection with its strategic partnership with The Priceline Group. The partnership…
Davis Polk Advises Tailwind Capital on the Sale of ReTrans
Davis Polk is advising Tailwind Capital in connection with the sale of ReTrans Inc. to The Kuehne + Nagel Group. The…
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common…
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by…